Tofersen
托夫生SOD1 antisense oligonucleotide newly added to the 2026 Commercial Health Insurance Innovative Drug List (#25) for adult SOD1-mutated ALS.
China Approval (NMPA)
Pending VerificationReimbursement catalog entries for this drug are verified from NHSA official PDFs. Individual NMPA registration certificate numbers (国药准字) and approval dates are queued for incremental verification.
National Reimbursement
Not ListedNot included in the 2025 or 2026 National Reimbursement Drug List (basic medical insurance).
Commercial Insurance List
Announced · Effective Jan 1, 2027- 2026 List Entry
- #25 · 凯盛迪
- Validity Period
- 2027-01-01 to 2028-12-31
- MAH / Authorized Entity
- Biogen MA Inc. · 渤健生物科技(上海)有限公司
- Listed Indication Scope
- Adult patients with amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 (SOD1) gene.
Catalog inclusion only. Actual reimbursement depends on individual commercial health insurance policy contracts.
Approved Products, Dosage Forms & Approval Numbers
0 verified NMPA recordsChange Timeline
- (2027-01-01)Commercial List· Catalog published: Nov 14, 2026
2026 Commercial List · Newly Added (#25)
Adult patients with amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 (SOD1) gene.
Chinese original: 本品用于治疗携带超氧化物歧化酶1(SOD1)基因突变的肌萎缩侧索硬化(ALS)成人患者。
NHSA · PDF p.4Verified 2026-11-20
Verified Names & Aliases
Every English INN, Chinese generic name, brand name, and R&D code is recorded with its source.
Primary Sources for This Record
- NHSAPublished 2026-11-14商业健康保险创新药品目录(2026年)Retrieved 2026-11-20
- WHO世界卫生组织国际非专利药名(INN)指南Retrieved 2026-11-20